{"denoms":[{"counts":[{"groupId":"BG000","value":"302"}],"units":"Participants"}],"groups":[{"description":"Open-label eltrombopag was supplied in 25, 50, 75 mg tablets. All subjects started at 50mg once daily and dose was increased or decreased based on platelet count (target range 50-200Gi/L). Alternate days and interruption of dosing was permitted to maintain target range of platelet count. Doses could range from 25 to 75mg. Subjects could remain on treatment up to 2 years.","id":"BG000","title":"Eltrombopag"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"15.61","value":"48.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"201"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"101"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"101"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"201"}]}],"title":"No"}],"paramType":"NUMBER","title":"Concomitant ITP Medication at Baseline","unitOfMeasure":"Participant"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"115"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"187"}]}],"title":"No"}],"paramType":"NUMBER","title":"Splenectomy Status at Baseline","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"211"}]}],"title":"<30 Gi/L"},{"categories":[{"measurements":[{"groupId":"BG000","value":"52"}]}],"title":"30 - 50 Gi/L"},{"categories":[{"measurements":[{"groupId":"BG000","value":"39"}]}],"title":"> 50 Gi/L"}],"paramType":"NUMBER","title":"Baseline Platelet Count","unitOfMeasure":"Participants"}]}